Treatment of Ezetimibe lowers total and low-density lipoprotein cholesterol in hypercholesterolemic dogs with hyperadorenocorticism.
J Vet Med Sci
; 86(4): 363-367, 2024 Apr 01.
Article
en En
| MEDLINE
| ID: mdl-38383002
ABSTRACT
Ezetimibe is a cholesterol absorption inhibitor that blocks the intestinal absorption of both biliary and dietary cholesterol, thereby lowering primarily low density lipoprotein-cholesterol (LDL-chol) in human studies. This study aimed to investigate the effects of ezetimibe on dyslipidemia control in nine dogs with hypercholesterolemia. Changes in total cholesterol (T-chol) and each lipoprotein fractions were evaluated at 0, 2, and 4 months following initiation of ezetimibe treatment. A significant decrease in T-chol was observed, and a mean T-chol concentration below 400 mg/dL was achieved at 2 and 4 months. Furthermore, a significant decrease in LDL-chol was observed (-53.3% and -64.3% at 2 and 4 months, respectively). Taken together, treatment of ezetimibe could lower LDL-chol levels in dogs with hypercholesterolemia.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Azetidinas
/
Enfermedades de los Perros
/
Hipercolesterolemia
/
Anticolesterolemiantes
Límite:
Animals
/
Humans
Idioma:
En
Revista:
J Vet Med Sci
Asunto de la revista:
MEDICINA VETERINARIA
Año:
2024
Tipo del documento:
Article
País de afiliación:
Japón